• Explore /
  • Poster
  • / A phase 2 single-arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pretreated with one immune checkpoint inhibitor: The BREAKPOINT trial (MeetUro trial 03-NCT03463681).

A phase 2 single-arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pretreated with one immune checkpoint inhibitor: The BREAKPOINT trial (MeetUro trial 03-NCT03463681).

Abstract Video & Slides Poster

Authors

null

Giuseppe Procopio

Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

Giuseppe Procopio , Melanie Claps , Chiara Pircher , Luca Porcu , Pierangela Sepe , Valentina Guadalupi , Ugo De Giorgi , Cristian Lolli , Marco Maruzzo , Franco Nole , Roberto Iacovelli , Cristina Masini , Cinzia Baldessari , Laura Doni , Antonio Cusmai , Angela Gernone , Sarah Scagliarini , Sandro Pignata , Filippo G. De Braud , Elena Verzoni

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Kidney and Bladder

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Kidney Cancer

Clinical Trial Registration Number

NCT03463681

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 4569)

DOI

10.1200/JCO.2021.39.15_suppl.4569

Abstract #

4569

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Giuseppe Procopio

First Author: Elena Verzoni

First Author: Geoffrey Thomas Gibney

First Author: Tae-Yong Kim